To explore observe the curative effect of rebamipide combined with esomeprazole in patients with erosive gastritis, and explore its effects on gastric function and inflammatory indexes.

A total of 208 patients with erosive gastritis admitted to Beijing Daxing District People's Hospital were enrolled and randomly divided into combined medication group (esomeprazole+ rebamipide, n=104) and single medication group (esomeprazole, n=104) between January and December 2022. After 8 weeks of continuous treatment, the curative effect and safety, changes in levels of gastric function indexes (gastrin, motilin), vascular endothelial function, inflammation, NOD-like receptor family pyrin domain containing 6 (NLRP6) and recombinant trefoil factor 2 (TFF2) in gastric mucosa before and after treatment were compared between the two groups.

After 8 weeks of continuous treatment, total response rate of treatment in combined medication group was higher than that in single medication group (89.42% vs. 76.92%, P<0.05). After treatment, levels of gastrin, motilin, nitric oxide and calcitonin gene-related peptide in combined medication group were higher than those in single medication group (P<0.05), while levels of vascular endothelial growth factor, tumor necrosis factor α, interleukin-6, NLRP6 and TFF2 were lower than those in single medication group (P<0.05). There was no statistically significant difference in the incidence of adverse drug reactions between the two groups during treatment (P>0.05).

The clinical curative effect of rebamipide combined with esomeprazole is significant in patients with erosive gastritis, which can improve gastric function, inhibit inflammation level at gastric injury sites, promote the repair of vascular endothelial function and reduce levels of NLRP6 and TFF2, and will not increase the adverse drug reactions.